Symptoms and Endoscopic Results in Consideration of Pretreatment
NCT ID: NCT00612404
Last Updated: 2008-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16255 participants
OBSERVATIONAL
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy
NCT03736824
Trial to Reduce Inappropriate Oesophagogastroduodenoscopies for Dyspepsia
NCT03205319
Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification
NCT01173484
Gastric Pathophysiology in Diabetes
NCT06068114
Impact of Timing of Premedication on Mucosal Visibility During Endoscopy-A Randomized Controlled Trial
NCT06581783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients with gastrointestinal disorders who need an endoscopy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Germany
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Richter, MD
Role: STUDY_CHAIR
Medical Department AstraZeneca Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1312004008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.